II期和III期试验失败情况：2013 - 2015年 - Suppr

Suppr

超能文献

Phase II and phase III failures: 2013-2015.

作者信息

Harrison Richard K

机构信息

Clarivate Analytics, 1500 Spring Garden Street, Philadelphia, Pennsylvania 19103, USA.

出版信息

Nat Rev Drug Discov. 2016 Dec;15(12):817-818. doi: 10.1038/nrd.2016.184. Epub 2016 Nov 4.

DOI:10.1038/nrd.2016.184

PMID:27811931

Abstract

摘要

相似文献

Phase II and phase III failures: 2013-2015.

Nat Rev Drug Discov. 2016 Dec;15(12):817-818. doi: 10.1038/nrd.2016.184. Epub 2016 Nov 4.

Trial watch: phase II and phase III attrition rates 2011-2012.

Nat Rev Drug Discov. 2013 Aug;12(8):569. doi: 10.1038/nrd4090.

Empowering phase II clinical trials to reduce phase III failures.

Pharm Stat. 2020 May;19(3):178-186. doi: 10.1002/pst.1980. Epub 2019 Nov 14.

GlaxoSmithKline ends aplaviroc trials.

AIDS. 2006 Mar 21;20(5):641. doi: 10.1097/01.aids.0000216362.59657.96.

Trial watch: phase III and submission failures: 2007-2010.

Nat Rev Drug Discov. 2011 Feb;10(2):87. doi: 10.1038/nrd3375.

Clinical trials referral resource. Current phase II and phase III clinical trials for pancreatic cancer.

Oncology (Williston Park). 2004 Jul;18(8):1008, 1013-4, 1016.

Traditional phase 1 and 2 studies in thoracic radiation oncology should be abandoned.

Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):487-9. doi: 10.1016/j.ijrobp.2014.05.044. Epub 2014 Sep 26.

Randomized phase II trials: misleading and unreliable.

J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20.

Clinical trials part II.

Surviv News (Atlanta Ga). 2002 Jul:12.

The transition from phase II to phase III studies.

J Clin Oncol. 2009 Mar 1;27(7):1150-1. doi: 10.1200/JCO.2008.21.1938. Epub 2009 Jan 26.

引用本文的文献

Development of a protocol complexity tool: a framework designed to stimulate discussion and simplify study design.

BMC Med Res Methodol. 2025 Aug 29;25(1):205. doi: 10.1186/s12874-025-02652-9.

Enhancing the confidence of potential targets enriched by similarity-centric models: the crucial role of the similarity threshold.

Front Pharmacol. 2025 Aug 8;16:1574540. doi: 10.3389/fphar.2025.1574540. eCollection 2025.

Licoisoflavone B and glabridin from Glycyrrhiza glabra as potent nucleoprotein antagonists of Lassa virus: insights from molecular docking, dynamics simulation, PCA, and DFT studies.

J Genet Eng Biotechnol. 2025 Sep;23(3):100544. doi: 10.1016/j.jgeb.2025.100544. Epub 2025 Aug 5.

Application of directed message-passing neural network to predict human oral bioavailability of pharmaceuticals.

J Comput Aided Mol Des. 2025 Aug 19;39(1):68. doi: 10.1007/s10822-025-00649-6.

Substituted 1,4-naphthoquinones for potential anticancer therapeutics: cytotoxic effects and QSAR-guided design of new analogs.

Comput Struct Biotechnol J. 2025 Jul 25;27:3492-3509. doi: 10.1016/j.csbj.2025.07.040. eCollection 2025.

Clinical trials in otology and neurotology: state of the science.

Front Neurol. 2025 Jul 24;16:1598789. doi: 10.3389/fneur.2025.1598789. eCollection 2025.

Biased Signaling and Its Role in the Genesis of Short- and Long-Acting β-Adrenoceptor Agonists.

Biochemistry. 2025 Aug 19;64(16):3585-3598. doi: 10.1021/acs.biochem.5c00148. Epub 2025 Aug 7.

Antimalarial Drug Repurposing of Epirubicin and Pelitinib in Combination with Artemether and Lumefantrine.

Pharmaceuticals (Basel). 2025 Jun 25;18(7):956. doi: 10.3390/ph18070956.

The topology of molecular representations and its influence on machine learning performance.

J Cheminform. 2025 Jul 21;17(1):109. doi: 10.1186/s13321-025-01045-w.

Traversing the Valley of Death for nanotechnology-based natural products: strategies and insights from pharmaceutical stakeholders.

Drug Deliv Transl Res. 2025 Jul 18. doi: 10.1007/s13346-025-01923-8.

本文引用的文献

The year's new drugs & biologics 2015 - part II:Trends and highlights that marked a complicated year.

Drugs Today (Barc). 2016 Feb;52(2):131-63. doi: 10.1358/dot.2016.52.2.2472346.

Trial watch: phase II and phase III attrition rates 2011-2012.

Nat Rev Drug Discov. 2013 Aug;12(8):569. doi: 10.1038/nrd4090.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验